It would also be interesting to investigate if NAM could reestablish treatment sensitivity in cases of resistance to distinct targeted therapies (e.g., tamoxifen or trastuzumab in hormone and HER2 positive breast cancer patients, respectively) or immunotherapy. Here, ERBB2 is linked to breast cancer.